Oxford Asset Management LLP Buys New Position in MacroGenics, Inc. (NASDAQ:MGNX)

Oxford Asset Management LLP purchased a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 27,410 shares of the biopharmaceutical company’s stock, valued at approximately $89,000.

A number of other institutional investors also recently made changes to their positions in MGNX. Wasatch Advisors LP increased its stake in shares of MacroGenics by 37.6% during the fourth quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company’s stock valued at $11,338,000 after acquiring an additional 952,691 shares during the period. Geode Capital Management LLC increased its position in shares of MacroGenics by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,433,217 shares of the biopharmaceutical company’s stock valued at $4,659,000 after purchasing an additional 26,341 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of MacroGenics by 12.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 744,902 shares of the biopharmaceutical company’s stock worth $2,421,000 after buying an additional 82,988 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of MacroGenics by 68.3% in the fourth quarter. JPMorgan Chase & Co. now owns 546,807 shares of the biopharmaceutical company’s stock valued at $1,777,000 after buying an additional 221,905 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in MacroGenics by 69.1% during the fourth quarter. Renaissance Technologies LLC now owns 538,523 shares of the biopharmaceutical company’s stock valued at $1,750,000 after buying an additional 220,100 shares in the last quarter. 96.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MGNX has been the topic of several research reports. StockNews.com cut shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. HC Wainwright dropped their target price on shares of MacroGenics from $4.00 to $2.00 and set a “neutral” rating on the stock in a report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.38.

MacroGenics Price Performance

MGNX stock opened at $1.64 on Tuesday. The firm has a market capitalization of $103.47 million, a P/E ratio of -1.04 and a beta of 2.23. MacroGenics, Inc. has a 52-week low of $0.99 and a 52-week high of $16.44. The company’s 50 day simple moving average is $1.80 and its 200-day simple moving average is $2.81.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. MacroGenics had a negative net margin of 69.07% and a negative return on equity of 89.42%. Sell-side analysts predict that MacroGenics, Inc. will post -1.06 EPS for the current fiscal year.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.